Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 17 (2), 429

The Role of Cannabinoids in Regulation of Nausea and Vomiting, and Visceral Pain

Affiliations
Review

The Role of Cannabinoids in Regulation of Nausea and Vomiting, and Visceral Pain

Zubair Malik et al. Curr Gastroenterol Rep.

Abstract

Marijuana derived from the plant Cannabis sativa has been used for the treatment of many gastrointestinal (GI) disorders, including anorexia, emesis, abdominal pain, diarrhea, and others. However, its psychotropic side effects have often limited its use. Several cannabinoid receptors, which include the cannabinoid receptor 1 (CB1), CB2, and possibly GPR55, have been identified throughout the GI tract. These receptors may play a role in the regulation of food intake, nausea and emesis, gastric secretion and gastroprotection, GI motility, ion transport, visceral sensation, intestinal inflammation, and cell proliferation in the gut. However, the regulation of nausea and vomiting by cannabinoids and the endocannabinoid system has shed new knowledge in this field. Thus far, despite evidence of visceral sensitivity inhibition in animal models, data in irritable bowel syndrome (IBS) patients is scarce and not supportive. Furthermore, many compounds that either act directly at the receptor or increase (or reduce) ligand availability have the potential to affect other brain functions and cause side effects. Novel drug targets such as FAAH and monoacylglycerol lipase (MAGL) inhibitors appear to be promising in animal models, but more studies are necessary to prove their efficiency. The promise of emerging drugs that are more selective and peripherally acting suggest that, in the near future, cannabinoids will play a major role in managing an array of GI diseases.

Similar articles

  • Cannabinoids and the Gut: New Developments and Emerging Concepts
    AA Izzo et al. Pharmacol Ther 126 (1), 21-38. PMID 20117132. - Review
    Cannabis has been used to treat gastrointestinal (GI) conditions that range from enteric infections and inflammatory conditions to disorders of motility, emesis and abdom …
  • Role of Cannabis in Digestive Disorders
    H Goyal et al. Eur J Gastroenterol Hepatol 29 (2), 135-143. PMID 27792038. - Review
    Cannabis sativa, a subspecies of the Cannabis plant, contains aromatic hydrocarbon compounds called cannabinoids. [INCREMENT]-Tetrahydrocannabinol is the most abundant ca …
  • Endocannabinoid System: A Multi-Facet Therapeutic Target
    R Kaur et al. Curr Clin Pharmacol 11 (2), 110-7. PMID 27086601. - Review
    Cannabis sativa is also popularly known as marijuana. It has been cultivated and used by man for recreational and medicinal purposes since many centuries. Study of cannab …
  • Cannabinoid Signaling in Health and Disease
    Y Lu et al. Can J Physiol Pharmacol 95 (4), 311-327. PMID 28263083. - Review
    Cannabis sativa has long been used for medicinal purposes. To improve safety and efficacy, compounds from C. sativa were purified or synthesized and named under an umbrel …
  • Therapeutic Potential of Cannabinoids in CNS Disease
    JL Croxford. CNS Drugs 17 (3), 179-202. PMID 12617697. - Review
    The major psychoactive constituent of Cannabis sativa, delta(9)-tetrahydrocannabinol (delta(9)-THC), and endogenous cannabinoid ligands, such as anandamide, signal throug …
See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles

References

    1. Diabetes Obes Metab. 2010 Jun;12(6):517-31 - PubMed
    1. J Pharmacol Sci. 2008 Feb;106(2):219-24 - PubMed
    1. Physiol Rev. 2009 Jan;89(1):309-80 - PubMed
    1. Mini Rev Med Chem. 2009 Jan;9(1):11-25 - PubMed
    1. Gastroenterology. 2005 Aug;129(2):437-53 - PubMed

MeSH terms

LinkOut - more resources

Feedback